Revolution Medicines, Inc.

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-10 pm EST			5-day change	1st Jan Change
41.78 ^USD	-5.94%		-5.30%	-4.48%

Jan. 08	UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating	MT
Dec. 06	Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating	MT

Revolution Medicines Closes Offering of 16.6 Million Shares

December 05, 2024 at 05:50 pm EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Revolution Medicines, Inc.

UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating	Jan. 08	MT
Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating	Dec. 06	MT
Revolution Medicines Closes Offering of 16.6 Million Shares	Dec. 05	MT
Revolution Medicines Prices $45 Million Stock, Warrant Offering	Dec. 04	MT
Revolution Medicines Launches $600 Million Offering of Common Shares	Dec. 02	MT
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating	Dec. 02	MT
Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies	Dec. 02	MT
Revolution Medicines, Inc. - Special Call	Dec. 02
Revolution Medicines, Inc. Provides Clinical Updates from Its RAS(ON) Inhibitor Portfolio	Dec. 02	CI
Revolution Medicines, Inc. Presents at UBS Global Healthcare Conference 2024, Nov-13-2024 02:00 PM	Nov. 13
Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance	Nov. 07	MT
Revolution Medicines, Inc., Q3 2024 Earnings Call, Nov 06, 2024	Nov. 06
Revolution Medicines, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 06	CI
Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024	Nov. 06	CI
Revolution Medicines Insider Sold Shares Worth $3,878,773, According to a Recent SEC Filing	Nov. 05	MT
Revolution Medicines, Inc. - Special Call	24-10-25
Revolution Medicines Says Potential Pancreatic Cancer Treatment Shows 'Encouraging' Initial Results	24-10-25	MT
Revolution Medicines, Inc. Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma	24-10-25	CI
Revolution Medicines, Inc. Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma	24-10-23	CI
Revolution Medicines Doses First Patient in Phase 3 Study of Pancreatic Cancer Drug	24-10-21	MT
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24-10-21	CI
Revolution Medicines Insider Sold Shares Worth $824,804, According to a Recent SEC Filing	24-10-16	MT
Revolution Medicines Insider Sold Shares Worth $1,510,773, According to a Recent SEC Filing	24-10-15	MT

Chart Revolution Medicines, Inc.

Duration

Period

RVMD: Dynamic Chart

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâs research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâs RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Employees

490

Sector

Biotechnology & Medical Research

Calendar

01:30pm - JP Morgan Healthcare Conference

More about the company